| Literature DB >> 35956977 |
Bartłomiej Zieniuk1, Chimaobi James Ononamadu2, Karina Jasińska1,3, Katarzyna Wierzchowska1,3, Agata Fabiszewska1.
Abstract
Green chemistry approaches, such as lipase-catalyzed esterification, are promising methods for obtaining valuable chemical compounds. In the case of the use of lipases, unlike in aqueous environments, the processes of the ester bond formations are encountered in organic solvents. The aim of the current research was to carry out the lipase-catalyzed synthesis of an ester of dihydrocaffeic acid. The synthesized compound was then evaluated for antioxidant and antimicrobial activities. However, the vast majority of its antioxidant activity was retained, which was demonstrated by means of DPPH· (2,2-diphenyl-1-picrylhydrazyl) and CUPRAC (cupric ion reducing antioxidant capacity) methods. Regarding its antimicrobial properties, the antifungal activity against Rhizopus oryzae is worth mentioning. The minimum inhibitory and fungicidal concentrations were 1 and 2 mM, respectively. The high antifungal activity prompted the use of molecular docking studies to verify potential protein targets for butyl ester of dihydrocaffeic ester. In the case of one fungal protein, namely 14-α sterol demethylase B, it was observed that the ester had comparable binding energy to the triazole medication, isavuconazole, but the interacted amino acid residues were different.Entities:
Keywords: Rhizopus oryzae; antifungal activity; butyl dihydrocaffeate; lipase-catalyzed synthesis; lipophilization; molecular docking
Mesh:
Substances:
Year: 2022 PMID: 35956977 PMCID: PMC9370587 DOI: 10.3390/molecules27155024
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Chemical structures of (a) dihydrocaffeic acid and (b) dopamine.
Figure 2Synthesis of dihydrocaffeic acid butyl ester catalyzed by lipase B from C. antarctica (CALB).
Comparison of the antioxidant activity of dihydrocaffeic acid, its butyl ester, and commonly known antioxidants by DPPH· and CUPRAC methods.
| DPPH· | CUPRAC | |||
|---|---|---|---|---|
| Compound | Methanol | Ethyl Acetate | Chloroform | (TEAC) |
| BDHC | 0.16 ± 0.01 Ca | 0.18 ± 0.01 Ba | 0.22 ± 0.01 Bb | 3.50 ± 0.03 A |
| DHCA | 0.12 ± 0.01 Aa | 0.14 ± 0.01 Ab | 0.15 ± 0.01 Ab | 2.73 ± 0.08 B |
| LAA | 0.28 ± 0.04 Da | 0.23 ± 0.02 Ca | 3.25 ± 0.08 b | 1.56 ± 0.01 D |
| BHT | 0.58 ± 0.03 Ea | 21.34 ± 1.55 c | 16.60 ± 1.79 b | 1.92 ± 0.01 C |
| GA | 0.09 ± 0.01 Aa | 0.13 ± 0.1 Ab | 0.17 ± 0.01 Ac | 3.37 ± 0.06 A |
| CA | 0.14 ± 0.01 Ba | 0.13 ± 0.01 Aa | 0.17 ± 0.01 Ab | 3.35 ± 0.09 A |
Abbreviations: BDHC: dihydrocaffeic acid butyl ester, DHCA: dihydrocaffeic acid, LAA: L-ascorbic acid, BHT: butylated hydroxytoluene, GA: gallic acid, CA: caffeic acid, TEAC: Trolox equivalent antioxidant capacity. Values with different capital letters in the column (A–E) differ statistically (α = 0.05). Values with different lowercase letters in the row within DPPH·method (a–c) differ statistically (α = 0.05).
Comparison of the antimicrobial activity of dihydrocaffeic acid butyl ester and its precursors.
| BDHC | DHCA | 1-Butanol | ||||
|---|---|---|---|---|---|---|
| MIC (mM) | MMC (mM) | MIC (mM) | MMC (mM) | MIC (mM) | MMC (mM) | |
| 16 | 32 | 16 | 32 | 32 | 64 | |
| 8 | 16 | 2 | 4 | 16 | 32 | |
| 4 | 8 | 16 | 32 | 16 | 32 | |
| 8 | 16 | 2 | >64 | 16 | >64 | |
| 8 | 16 | 8 | 16 | 16 | 64 | |
| 4 | 8 | 2 | 4 | 16 | >64 | |
| 1 | 2 | 32 | >64 | 32 | >64 | |
Abbreviations: BDHC: dihydrocaffeic acid butyl ester, DHCA: dihydrocaffeic acid, MIC: minimum inhibitory concentration, MMC: minimum microbicidal concentration.
Figure 3Comparison of the diameter of the R. oryzae DSM 2199 mycelium on PDA medium containing the tested ester in concentrations of 0–2 mM. Asterisks (*) annotate the statistical difference (by Dunnett test) in inhibiting the mycelial growth by the tested compound in selected concentration in comparison with control (0 mM). For 2 mM ester concentration no R. oryzae growth was observed.
Figure 4Photographs of R. oryzae mycelium after 4 days of cultivation on PDA medium containing the tested ester at the concentration of (a) 0, (b) 0.5 and (c) 1 mM, respectively.
Comparison of selected physicochemical descriptors, pharmacokinetic properties, drug-likeness, and ADME (absorption, distribution, metabolism, and excretion) parameters of dihydrocaffeic acid butyl ester and its precursor.
| DHCA | BDHC | Reference Value * | |
|---|---|---|---|
| Molecular weight (g/mol) | 182.17 | 238.28 | <500 |
| Hydrogen bond donors | 3 | 2 | <5 |
| Hydrogen bond acceptors | 4 | 4 | <10 |
| Rotatable bonds | 3 | 7 | <10 |
| Molar refractivity | 46.48 | 65.58 | |
| TPSA (Ų) | 77.76 | 66.76 | ≤140 |
| LogP | 0.63 | 2.44 | <5 |
| LogS | −0.62 | −4.42 | |
| Rule of five violations | 0 | 0 | |
| Gastrointestinal absorption | High | High | |
| The blood–brain barrier permeant | No | Yes |
* The drug-likeness reference values declared based on Lipinski’s [33] and Veber’s [34] guidelines. Abbreviations: DHCA: dihydrocaffeic acid, BDHC: dihydrocaffeic acid butyl ester, TPSA: topological polar surface area, LogP: partition coefficient (measure of lipophilicity), LogS: water solubility.
Figure 5Visualizations of docking analysis of glutamine-fructose-6-phosphate transaminase (GFAT) binding with butyl dihydrocaffeate: (a,b) 3D visualizations, (c) 2D binding interactions, and 14-α sterol demethylase B binding with butyl dihydrocaffeate: (d,e) 3D visualizations, (f) 2D binding interactions.
Figure 6Visualizations of docking analysis of Invasin CotH3 binding with butyl dihydrocaffeate: (a,b) 3D visualizations, (c) 2D binding interactions, and Mucoricin binding with butyl dihydrocaffeate: (d,e) 3D visualizations, (f) 2D binding interactions.
Molecular docking scores of the query ligands docked to target proteins (glutamine-fructose-6-phosphate transaminase (GFAT), 14-α sterol demethylase B, Invasin CotH3, and Mucoricin).
| Target Protein | Compound | Binding Energy (kcal/mol) | Interacting Amino Acid Residues |
|---|---|---|---|
| Glutamine-fructose-6-phosphate transaminase (GFAT) | Posaconazole | −7.5116 | a Glu567, b Ser428, c Ser382 |
| Isavuconazole | −5.8663 | a Glu567, b Ser428 | |
| 12,28-Oxamanzamine A | −6.1423 | b Glu567, b Thr381 | |
| DHCA | −4.1152 | b Ser479 | |
| BDHC | −5.1152 | b Ser479 | |
| 14-α sterol | Posaconazole | −9.7030 | a Cys455, c Tyr133, c Phe222 |
| Isavuconazole | −6.1767 | a His453, b Gly294, c Val291, c Cys455 | |
| 12,28-Oxamanzamine A | −4.0297 | a Met494 | |
| DHCA | −4.5334 | a Met494 | |
| BDHC | −6.1416 | a Met116 | |
| Invasin CotH3 | Posaconazole | −8.9723 | a Ala303, c Lys180 |
| Isavuconazole | −7.3442 | c Gly179, c Lys180 | |
| 12,28-Oxamanzamine A | −7.3644 | a Asn368, a Asp387, e His176, c Thr367, d Asp387 | |
| DHCA | −4.9011 | b Asn368, b Gln386 | |
| BDHC | −6.3490 | a Glu212, c Lys180 | |
| Mucoricin | Posaconazole | −6.5630 | a Glu23 |
| Isavuconazole | −5.4709 | a Glu41, a Asp21 | |
| 12,28-Oxamanzamine A | −5.5611 | aGlu41 | |
| DHCA | −4.3442 | a Asp21, b Lys59 | |
| BDHC | −4.6642 | a Asp21 |
a: H-donor, b: H-acceptor, c: Pi-H bond, d: Ionic, e: H-Pi, Abbreviations: DHCA: dihydrocaffeic acid, BDHC: dihydrocaffeic acid butyl ester.